期刊文献+

吉西他滨联合顺铂治疗晚期三阴性乳腺癌临床观察 被引量:4

下载PDF
导出
摘要 目的观察吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效、不良反应及预后。方法选用GD方案:吉西他滨(gemcitabine,GEM)1 000 mg/m^2,静滴,d1、d8;顺铂(cisplatin,DDP)25 mg/m^2,静滴,d2-d4。21 d为1个周期,连用2个周期或2个周期以上,治疗2011年1月至2014年12月扬州市江都人民医院收治的晚期三阴性乳腺癌,并对治疗效果、不良反应进行分析。结果共入组47例。完成化疗2-8个周期(中位化疗5个周期)。47例化疗总有效率为46.81%,肿瘤控制率82.98%。毒副反应主要为骨髓毒性和消化道反应,其中Ⅲ-Ⅳ级者以中性粒细胞减少(38.29%)、血小板减少(21.28%)为主。其他毒副反应有便秘(25.53%)、骨痛(8.51%),均为Ⅰ-Ⅱ级。患者中位TTP为8.2个月,死亡18例,中位OS为19.1个月,1年生存率为73.1%,2年生存率为45.1%。结论吉西他滨联合顺铂方案治疗晚期三阴性乳腺癌近期效果较好,毒性可耐受,是蒽环类/紫杉类药物治疗失败后较好的救援方案。
出处 《中国肿瘤外科杂志》 CAS 2016年第6期407-408,410,共3页 Chinese Journal of Surgical Oncology
  • 相关文献

参考文献1

二级参考文献24

  • 1Dickler MN, Barry WT, Cirrincione CT, et al. Phase m trial e- valuating the addition of bevacizumab to letrozole as first-line endo- crine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance) [ C ]. J Clin Oncol, 2015, 33 ( suppl aS01 ). 被引量:1
  • 2Gralow J, Barlow WE, Paterson AHG, et al. Phase R[ trial of bi- sphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307 [ C ]. J Clin Oncol, 2015, 33 (suppl a503). 被引量:1
  • 3Gnant M, Pfeiler G, Duhsky PC, et al. Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial[ C ]. J Clin Oncol, 2015, 33 ( suppl a504). 被引量:1
  • 4Gianni L, Pienkowski T, Im YH, et al. Five-year analysis of the phase ]I NeoSphere trial evaluating four cycles of neoadjuvant do- cetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P) [ C ]. J Clin Oncol, 2015, 33 (suppl a505). 被引量:1
  • 5Harbeck N, Ghz O, Christgen M, et al. Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2- positive hormone-receptor-positive early breast cancer: WSG-A- DAPT HER2 +/HR + phase II trial[C]. J Clin Oncol, 2015, 33 ( suppl a506 ). 被引量:1
  • 6Ellis PA, Barrios CH, Eiermann W,et al. Phase 111, randomized study of trastuzumab emtansine (T-DM1) + pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of I-IER2-posi- tive MBC: Primary results from the MARIANNE study[ C]. J Clin Oncol, 2015, 33(suppl a507). 被引量:1
  • 7Chan A, Delaloge S, Holmes FA, et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast canc- er: Primary analysis at 2 years of a phase 3, randomized, placebo- controlled trial (ExteNET) [ C ]. J Clin Oncol, 2015, 33 ( suppl a508). 被引量:1
  • 8Stover DG, Selfors LM, Coloff JL, et al. Meta-analysis of breast cancer expression data using published gcne signatures to reveal key cellular processes implicated in chemosensitivity and resistance [ C]. J Clin Oncol, 2015, 33( suppl a509). 被引量:1
  • 9Vinayak S, Gray P,J, Adams S, et al. Association of increased tumor-infiltrating lymphocytes ( TILs ) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to nenadjuvant platinum-based therapy in PrECOGO105 [ C ]. J Clin Oncol, 2014,32:5 s ( suppl alO00 ). 被引量:1
  • 10Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8 ~ and FOXP3 ~ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer[ C ]. J Clin Oncol, 2015, 33 ( suppl a510). 被引量:1

共引文献8

同被引文献63

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部